Triple HER2-blockade with lapatinib, trastuzumab, and pertuzumab for treatment of HER2 positive metastatic breast cancer with lymphangitic carcinomatosis: A case study

Triple HER2-blockade with lapatinib, trastuzumab, and pertuzumab for treatment of HER2 positive metastatic breast cancer with lymphangitic carcinomatosis: A case study

There are many options for treating human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC), and the best sequential or salvage treatment is still debated. This report outlines a case of a 59-year-old woman with HER2-positive MBC. She received HER2 triple blockade tre...

Full description

Bibliographic Details
Main Authors: Kazuki Nozawa, Daiki Takatsuka, Yuka Endo, Nanae Horisawa, Yuri Ozaki, Ayumi Kataoka, Haruru Kotani, Akiyo Yoshimura, Masaya Hattori, Masataka Sawaki, Hiroji Iwata
Format: Article
Language:English
Published: Elsevier 2022-09-01
Series:Current Problems in Cancer: Case Reports
Subjects:
HER2 breast cancer
Lapatinib
Pertuzumab
Trastuzumab
Online Access:http://www.sciencedirect.com/science/article/pii/S2666621922000473

Internet

http://www.sciencedirect.com/science/article/pii/S2666621922000473

Similar Items